HT-29細(xì)胞

生長狀態(tài)： 貼壁生長

是否是腫瘤細(xì)胞： 1

物種來源： 人

數(shù)量： 大量

ATCC Number： HTB-38?

相關(guān)**： 大腸癌

器官來源： 結(jié)腸

年限： 44 years *****

運(yùn)輸方式： 凍存運(yùn)輸

細(xì)胞形態(tài)： 上皮樣

Designations: HT-29

HT-29細(xì)胞Depositors: J Fogh

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial

Source: Organ: colon

Disease: colorectal adenocarcinoma

Cellular Products: secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth factor beta binding protein; mucin

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. HT-29細(xì)胞Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: The cells are distributed for research purposes only. The Memorial Sloan-Kettering Cancer Center releases the line subject to the following: 1.) The cells or their products must not be distributed to third parties. Commercial interests are the exclusive property of Memorial Sloan-Kettering Cancer Center. 2.) Any proposed commercial use of these cells must first be negotiated with The Director, Office of Industrial Affairs, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; phone (212) 639-6181; FAX (212) 717-3439.

Isolation: Isolation date: 1964

Applications: transfection host (Roche Transfection Reagents)

Receptors: human adrenergic alpha2A [23560]

urokinase receptor (u-PAR)

vitamin D (moderate expression)

urokinase receptor (u-PAR); vitamin D (moderate expression)

Tumorigenic: Yes

Oncogene: myc +; ras +; myb +; fos +; sis +; p53 +; abl -; ros -; src -

Antigen Expression: Blood Type A; Rh+; HLA A1, A3, B12, B17, Cw5

DNA Profile (STR): HT-29細(xì)胞Amelogenin: X

CSF1PO: 11,12

D13S317: 11,12

D16S539: 11,12

D5S818: 11,12

D7S820: 10

THO1: 6,9

TPOX: 8,9

vWA: 17,19

Cytogenetic Analysis: modal number = 71; range = 68 to 72.

HT-29細(xì)胞The stemline chromosome number is hypertriploid with the 2S component occurring at 2.4%. Seventeen marker chromosomes are found in most metaphases, generally in single copy per chromosome. The marker designations are: M1p-(=t(3p-;?) with a deleted short arm), t(7q;?), t(10q;?), i(13q), 19q+a; M6, ?t(8q;9q-), ?Xp, M9, 6q+, t(13;?)a, t(13;?)b, 19q+b, M14, M15, 15p+, and Xq-. Chromosome 13 is nullisomic and chromosomes 8 and 14 are generally monosomic. No Y chromosome was detected by QM band analysis.

Isoenzymes: AK-1, 1

ES-D, 1

G6PD, B

GLO-I, 1-2

Me-2, 1

PGM1, 1-2

PGM3, 1-2

Age: 44 years *****

Gender: female

Ethnicity: Caucasian

Comments: HT-29細(xì)胞Ultrastructural features reported for HT-29 cells include microvilli, microfilaments, large vacuolated mitochondria with dark granules, smooth and rough endoplasmic reticulum with free ribosomes, lipid droplets, few primary and many secondary lysosomes. The cells express urokinase receptors, but do not have detectable plasminogen activator activity [PubMed ID: 8381394]. HT-29 cells are negative for CD4, but there is cell surface expression of galactose ceramide (a possible alternative receptor for HIV). The line is positive for expression of c-myc, K-ras, H-ras, N-ras, Myb, sis and fos oncogenes. The p53 antigen is overproduced, and there is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution. N-myc oncogene expression was not detected.

There is a G -> A mutation in codon 273 of the p53 gene resulting in an Arg -> His substitution.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated McCoy's 5a Medium Modified, Catalog No. 30-2007. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Atmosphere: air, 95%; carbon dioxide (CO2), 5%

Temperature: 37.0°C

Subculturing: Protocol:

Remove and discard culture medium.

Briefly rinse the cell layer with 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.

Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).

Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.

Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.

Add appropriate aliquots of the cell suspension to new culture vessels.

Incubate cultures at 37C.

Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:8 is recommended

Medium Renewal: 2 to 3 times per week

Preservation: Freeze medium: Complete growth medium, 95%; DMSO, 5%

Storage temperature: liquid nitrogen vapor temperature

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2007

recommended serum:ATCC 30-2020

derivative:ATCC CCL-218

purified DNA:ATCC HTB-38D

References: 18385: Didier ES, et al. Characterization of Encephalitozoon (Septata) intestinailis isolates cultured from nasal mucosa and bronchoalveolar lavage fluids of two AIDS patients. J. Eukaryot. Microbiol. 43: 34-43, 1996. PubMed: 8563708

21869: . Human tumor cells in vitro. New York: Plenum Press; 1975.

22411: Chen TR, et al. WiDr is a derivative of another colon adenocarcinoma cell line, HT-29. Cancer Genet. Cytogenet. 27: 125-134, 1987. PubMed: 3472642

22536: Fogh J, et al. Absence of HeLa cell contamination in 169 cell lines derived from human tumors. J. Natl. Cancer Inst. 58: 209-214, 1977. PubMed: 833871

22539: Fogh J, et al. One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst. 59: 221-226, 1977. PubMed: 327080

22564: Adachi A, et al. Productive, persistent infection of human colorectal cell lines with human immunodeficiency virus. J. Virol. 61: 209-213, 1987. PubMed: 3640832

22570: Fantini J, et al. Human colon epithelial cells productively infected with human immunodeficiency virus show impaired differentiation and altered secretion. J. Virol. 66: 580-585, 1992. PubMed: 1727501

22807: Butzow R, et al. A 60-kD protein mediates the binding of transforming growth factor-beta to cell surface and extracellular matrix proteoglycans. J. Cell Biol. 122: 721-727, 1993. PubMed: 8335695

22861: Trainer DL, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int. J. Cancer 41: 287-296, 1988. PubMed: 3338874

22866: Hanski C, et al. Tumorigenicity, mucin production and AM-3 epitope expression in clones selected from the HT-29 colon carcinoma cell line. Int. J. Cancer 50: 924-929, 1992. PubMed: 1372882

22867: Reiter LS, et al. The role of the urokinase receptor in extracellular matrix degradation by HT29 human colon carcinoma cells. Int. J. Cancer 53: 444-450, 1993. PubMed: 8381394

22996: Barnett SW, et al. Characterization of human immunodeficiency virus type 1 strains recovered from the bowel of infected individuals. Virology 182: 802-809, 1991. PubMed: 2024498

23105: Shabahang M, et al. 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res. 53: 3712-3718, 1993. PubMed: 8393379

23154: Lesuffleur T, et al. Differential expression of the human mucin genes MUC1 to MUC5 in relation to growth and differentiation of different mucus-secreting HT- 29 cell subpopulations. J. Cell Sci. 106: 771-778, 1993. PubMed: 8308060

23226: Pollack MS, et al. HLA-A, B, C and DR alloantigen expression on forty-six cultured human tumor cell lines. J. Natl. Cancer Inst. 66: 1003-1012, 1981. PubMed: 7017212

23335: Fantini J, et al. Infection of colonic epithelial cell lines by type 1 human immunodeficiency virus is associated with cell surface expression of galactosylceramide, a potential alternative gp120 receptor. Proc. Natl. Acad. Sci. USA 90: 2700-2704, 1993. PubMed: 8464878

23560: Devedjian JC, et al. Regulation of the alpha 2A-adrenergic receptor in the HT29 cell line. Effects of insulin and growth factors. J. Biol. Chem. 266: 14359-14366, 1991. PubMed: 1677644

25093: Santoro IM, Groden J. Alternative splicing of the APC gene and its association with terminal differentiation. Cancer Res. 57: 488-494, 1997. PubMed: 9012479

32248: Bermudez LE, et al. Exposure to low oxygen tension and increased osmolarity enhance the ability of Mycobacterium avium to enter intestinal epithelial (HT-29) cells. Infect. Immun. 65: 3768-3773, 1997. PubMed: 9284150

32265: Tsao H, et al. Novel mutations in the p16/CDKN2A binding region of the Cyclin-dependent Kinase-4 gene. Cancer Res. 58: 109-113, 1998. PubMed: 9426066

32282: Qian XC, Brent TP. Methylation hot spots in the 5' flanking region denote silencing of the O6-methylguanine-DNA methyltransferase gene. Cancer Res. 57: 3672-3677, 1997. PubMed: 9288770

32297: Morin PJ, et al. Apoptosis and APC in colorectal tumorigenesis. Proc. Natl. Acad. Sci. USA 93: 7950-7954, 1996. PubMed: 8755583

32376: White LJ, et al. Attachment and entry of recombinant norwalk virus capsids to cultured human and animal cell lines. J. Virol. 70: 6589-6597, 1996. PubMed: 8794293

32396: Kolanus W, et al. alphaLbeta2 integrin/LFA-1 binding to ICAM-1 induced by cytohesin-1 a cytoplasmic regulatory molecule. Cell 86: 233-242, 1996. PubMed: 8706128

32910: Wang R, et al. Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. Proc. Natl. Acad. Sci. USA 93: 8425-8430, 1996. PubMed: 8710887

32923: Young SW, et al. Gadolinium(III) texaphyrin: a tumor selective radiation sensitizer that is detectable by MRI. Proc. Natl. Acad. Sci. USA 93: 6610-6615, 1996. PubMed: 8692865

32929: Groh V, et al. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93: 12445-12450, 1996. PubMed: 8901601

33045: Takahashi K, et al. Keratan sulfate modification of CD44 modulates adhesion to hyaluronate. J. Biol. Chem. 271: 9490-9496, 1996. PubMed: 8621620